Glucagon-Like Peptide 1-Based Therapies and Risk of Pancreatic Cancer in Patients With Diabetes and Obesity.
糖尿病和肥胖患者中胰臟癌風險的胰高血糖素樣肽1基礎治療。
Pancreas 2023-05-01
Lower risks of cirrhosis and hepatocellular carcinoma with GLP-1RAs in type 2 diabetes: A nationwide cohort study using target trial emulation framework.
GLP-1RAs在2型糖尿病患者中降低肝硬化和肝細胞癌風險:使用目標試驗模擬框架的全國性 cohort 研究。
J Intern Med 2024-02-14
Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes.
二型糖尿病患者中胰臟癌風險與葡萄糖樣肽-1受體激動劑的關聯。
JAMA Netw Open 2024-01-08
Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials.
葡萄糖樣肽-1 受體激動劑與癌症風險的關聯性:來自藥物靶點 Mendelian 隨機化和臨床試驗的證據。
Int J Surg 2024-05-03
The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study.
糖尿病患者使用 GLP-1 受體激動劑不會增加胰臟癌風險:美國基礎的世代研究。
Cancers (Basel) 2024-05-13
Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes.
糖尿病患者中胰高血糖素樣肽-1受體激動劑與13種與肥胖相關的癌症。
JAMA Netw Open 2024-07-05
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Gastrointestinal Cancers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
胰高血糖素樣肽-1 受體激動劑與胃腸道癌症風險:隨機對照試驗的系統性回顧與統合分析。
Pharmacol Res 2024-09-09